Forskning 2007 - Herlev Hospital

Forskning 2007 - Herlev Hospital

Forskning 2007

Hojman P, Zibert JR, Gissel H, Eriksen J, Gehl J.

Gene expression profiles in skeletal muscle after gene

electrotransfer. Bmc Molecular Biology 2007;8.

Krarup-Hansen A, Helweg-Larsen S, Schmalbruch

H, Rorth M, Krarup C. Neuronal involvement in

cisplatin neuropathy: prospective clinical and

neurophysiological studies. Brain : a journal of

neurology 2007 Apr;130(Pt 4):1076-88.

Labanauskiene J, Gehl J, Didziapetriene J. Evaluation

of cytotoxic effect of photodynamic therapy

in combination with electroporation in vitro.

Bioelectrochemistry 2007;70(1):78-82.

Larsen UL, Olesen LH, Nyvold CG, Eriksen J, Jakobsen

P, Ostergaard M, Autrup H, Andersen V. Human

intestinal P-glycoprotein activity estimated by the

model substrate digoxin. Scandinavian Journal of

Clinical & Laboratory Investigation 2007;67(2):123-34.

Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlo

C, Jensen BV. Cetuximab and irinotecan as third

line therapy in patients with advanced colorectal

cancer after failure of irinotecan, oxaliplatin and 5-

fluorouracil. Acta Oncol 2007;46(5):697-701.

Roslind A, Johansen JS, Junker N, Nielsen DL,

Dzaferi H, Price PA, Balslev E. YKL-40 expression

in benign and malignant lesions of the breast: A

methodologic study. Applied Immunohistochemistry &

Molecular Morphology 2007;15(4):371-81.

Sorensen RB, Hadrup SR, Kollgaard T, Svane IM,

Straten PT, Andersen MH. Efficient tumor cell lysis

mediated by a Bcl-X(L) specific T cell clone isolated

from a breast cancer patient. Cancer Immunology

Immunotherapy 2007;56(4):527-33.

Svane IM, Pedersen AE, Johansen JS, Johnsen HE,

Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal

E, Nikolajsen K, Claesson MH. Vaccination with

p53 peptide-pulsed dendritic cells is associated with

disease stabilization in patients with p53 expressing

advanced breast cancer; monitoring of serum YKL-40

and IL-6 as response biomarkers. Cancer Immunology

Immunotherapy 2007;56(9):1485-99.

Svane IM, Nikolajsen K, Johnsen HE. Antigen-specific T-

cell immunity in multiple myeloma patients is restored

following high-dose therapy: Implications for timing of

vaccination. Scand J Immunol 2007;66(4):465-75.


Als AB, Sengelov L, Von Der MH. Gemcitabine and

cisplatin in locally advanced and metastatic bladder

cancer; 3- or 4-week schedule? Acta oncologica

(Stockholm, Sweden) 2007 Jul 13;1-10.

Als AB, Sengelov L, von der Maase H. Long-term

survival after gemcitabine and cisplatin in patients

with locally advanced transitional cell carcinoma of the

bladder: Focus on supplementary treatment strategies.

Eur Urol 2007;52(2):478-87.

Andersen M, Horn T, Krarup-Hansen A, Norgard H,

Hendel HW, Bergenfeldt M. Retroperitonealt sarkom:

et multidisciplinaert samarbejde. Ugeskrift for laeger

2007 Aug 20;169(34):2786-7.

Andersen MH, Svane IM, Becker JC, Straten PT. The

universal character of the tumour-associated antigen

survivin. Clin Cancer Res 2007;13(20):5991-4.

Andersson M, Nielsen DL. Medicinsk efterbehandling

af primaer cancer mammae: nyere malrettede

biologiske behandlinger. Ugeskrift for laeger 2007 Sep


Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K.

Anthracycline-induced chronic cardiotoxicity and heart

failure. Acta Oncol 2007;46(5):576-80.

Appel JM, Rybjerg M, Nielsen DL. Kardiotoksicitet

ved antracyklinbehandling: betydning af infusionsvarigheden.

Analyse af et Cochrane-review. Ugeskrift

for laeger 2007 Sep 10;169(37):3105-7.

Ejlertsen B, Kamby C. Medicinsk behandling af

primaer cancer mammae: kemoterapi. Ugeskrift for

laeger 2007 Sep 10;169(37):3070-2.

Herrstedt J. Chemotherapy-induced nausea and

vomiting: ESMO clinical recommendations for prophylaxis.

Annals of oncology : official journal of the

European Society for Medical Oncology / ESMO 2007

Apr;18 Suppl 2:ii83-ii85.

Herrstedt J. Medikamentel behandling af kemoterapiinduceret

kvalme og opkastning. Ugeskrift for laeger

2007 Feb 26;169(9):799-805.

Herrstedt J, Dombernowsky P. Anti-emetic therapy

in cancer chemotherapy: Current status. Basic & Clinical

Pharmacology & Toxicology 2007;101(3):143-50.

Holmberg O. Accident prevention in radiotherapy.

Biomed Imaging Interv J 2007;3(2):e27.Jensen AB,

Kamby C, Hansen B, Keller J. Knoglemetastaser.

Ugeskrift for laeger 2007 Oct 29;169(44):3753-6.

Jensen AB, Kamby C, Hansen B, Keller J. Knoglemetastaser.

Ugeskrift for laeger 2007 Oct 29;169(44):3753-6.

Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-

40 a new therapeutic target in cancer? Expert Opinion

on Therapeutic Targets 2007;11(2):219-34.


More magazines by this user
Similar magazines